| Message:
Page 1
Select search result to email or save
1
J BUON
Sep-Oct 2020;25(5):2144-2146.
Micro-RNAs signatures in papillary thyroid carcinoma
Nicholas Mastronikolis 1, Evangelos Tsiambas, Dimitrios Roukas, Panagiotis Fotiades, Aristeidis Chrysovergis, Vasileios Papanikolaou, Efthymios Kyrodimos, Sofianiki Mastronikoli, Athanasios Niotis, Vasileios Ragos
Affiliations expand
PMID: 33277828
Free article
Abstract
Among biomarkers that should be useful for a molecular discrimination of patients regarding treatment strategies and prognosis in solid malignancies, novel micro-RNAs (miRs) are under investigation. Quite recently, miRs are considered very promising and significant genetic markers for categorizing patients by their molecular characteristics, as well as extending their complicated genetic signatures. miRs are short, non-coding RNAs consisting of 20-25 nucleotides located at intra- or inter-gene regions. Functional miRs mediate a positive regulation of posttranscriptional gene silencing. Their deregulation in cancer cells due to genetic (e.g., mutations, translocations), epigenetic (e.g., DNA hyper-methylation of tumor suppressor genes, extensive genomic DNA hypo-methylation, aberrant histone modification patterns) and transcriptional alterations lead to a loss of miRs-mediated repression of target mRNA. Interestingly, a biphasic role of miRs in cancers of different histogenetic origin has been confirmed. In some of them, their upregulation is correlated with an increased oncogenic activity, whereas in others, the same miR type acts as a suppressor agent. Thyroid carcinoma comprises different histological subtypes, such as papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid cancer (ATC), and medullary thyroid carcinoma. In the current molecular review, we explored the role of a specific fraction of miRs in PTC subtype by categorizing them according to their up- or down-regulation status.
full-text links
full-text provider logo
Proceed to details Cite
Share
2
J BUON
Sep-Oct 2020;25(5):2523-2524.
Society-oriented Journalism and Scientific Publications
Dimitrios Moris 1
Affiliations expand
PMID: 33277878
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
3
J BUON
Sep-Oct 2020;25(5):2530.
COVID-19 pandemic and some observations about management of breast cancer at private practice
Kadri Altundag 1
Affiliations expand
PMID: 33277884
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
4
J BUON
Sep-Oct 2020;25(5):2528.
Machine learning, AI, and breast cancer: A rallying call to drive adoption
Emir Roach 1, Kadri Altundag
Affiliations expand
PMID: 33277881
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
5
J BUON
Sep-Oct 2020;25(5):2531.
Is there any association between conversion rates of HER2 status and metastatic sites in breast cancer patients?
Kadri Altundag 1
Affiliations expand
PMID: 33277887
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
6
J BUON
Sep-Oct 2020;25(5):2529.
T1b with ER negative, HER2-positive, and node-negative breast cancer patients might get benefit from adjuvant chemotherapy
Kadri Altundag 1
Affiliations expand
PMID: 33277883
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
7
J BUON
Sep-Oct 2020;25(5):2530.
Association between common risk factors and molecular subtypes of breast cancer: Still debatable issue?
Kadri Altundag 1
Affiliations expand
PMID: 33277885
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
8
J BUON
Sep-Oct 2020;25(5):2412-2417.
Anticancer effects of ovatodiolide on human prostate cancer cells involves cell cycle arrest, apoptosis and blocking of Ras/Raf/MEK/ERK signaling pathway
Dongsheng Jia 1, Jianbo Zheng, Junli Yu, Ning Zhao, Shengxing Lu, Dongfang Hao
Affiliations expand
PMID: 33277863
Free article
Abstract
Purpose: The current research was set with a goal to characterize the anticancer role of ovatodiolide against human prostate cancer along with the underlying mechanism of its action.
Methods: The proliferation of prostate cancer cells was assessed by using the CCK8 reagent. DAPI and acridine orange (AO)/ ethidium bromide (EB) staining procedures were employed for the analysis of cell apoptosis. Flow cytometric examination of prostate cancer cells was undertaken for the mitotic cell cycle analysis. The western blotting technique was used for the inference of expression levels of the proteins of interest.
Results: In vitro administration of ovatodiolide led to decline of proliferation of prostate cancer cells. The reduction in proliferative rates was attributed to the induction of apoptosis of prostate cancer cells and mitotic cell cycle arrest. Furthermore, the anticancer effects of ovatodiolide on prostate cancer cells were exerted through the inhibition of Ras/Raf/MEK/ERK signaling cascade.
Conclusion: This study established the anticancer role of diterpenoid ovatodiolide in restricting the growth and proliferation of human prostate cancer cells.
full-text links
full-text provider logo
Proceed to details Cite
Share
9
J BUON
Sep-Oct 2020;25(5):2529.
Should estrogen receptor positive and progesterone receptor negative and HER-2 negative breast cancer patients be considered as a luminal B subtype?
Kadri Altundag 1
Affiliations expand
PMID: 33277882
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
10
J BUON
Sep-Oct 2020;25(5):2528.
Chimeric antigen receptor macrophages for breast cancer: An emerging treatment modality
Emir Roach 1, Kadri Altundag
Affiliations expand
PMID: 33277880
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
11
J BUON
Sep-Oct 2020;25(5):2531.
Physiotherapists should be included in multidisciplinary team treating breast cancer patients with axillary lymph nodes dissection
Seda Guler 1, Kadri Altundag
Affiliations expand
PMID: 33277886
Free article
No abstract available
full-text links
full-text provider logo
Proceed to details Cite
Share
12
J BUON
Sep-Oct 2020;25(5):2154-2159.
Clinicopathologic features and prognosis of histologic subtypes in the right-sided colon cancer
Serkan Zenger 1, Bulent Gurbuz, Ugur Can, Emre Balik, Dursun Bugra
Affiliations expand
PMID: 33277830
Free article
Abstract
Purpose: Differentiation of the histopathologic subtypes can be clinically important as it can affect the course of treatment and the prognosis. The aim of this study was to investigate both the clinicopathological features and prognosis of histologic subtypes in right-sided colon cancer.
Methods: This study included 138 patients who underwent surgery for right-sided colon cancer. The patients were divided into three groups according to histopathological subtypes as follows: medullary carcinoma (MC, n=11), mucinous adenocarcinoma (MAC, n=29), and classic adenocarcinoma (AC, n=98). The groups were compared in terms of demographic characteristics, type of surgery, pathological outcomes and survival.
Results: The rate of laparoscopic surgery was significantly lower in the MC group compared with MAC and AC groups (45.4% vs 54.5% vs 35.7%, respectively, p=0.001). In MC group, T4 stage was significantly higher than in other groups (90.0% vs 34.5% vs 35.7%, respectively, p=0.001). While patients with MAC had no distant metastasis, 18.2% and 15.3% of patients with MC and AC respectively, had distant metastasis (p=0.07). MAC vs MC, p=0.01, MAC vs AC, p=0.03). Tumor size, tumor volume, and the rate of microsatellite instability were found significantly higher in the MC group (p<0.05). The 5-year overall (OS) and disease-free survival (DFS) were better in the MAC group compared with MC and AC groups, but these differences did not reach statistical significance (OS: 92.8% vs 72.7% and 68.7%, p=0.16 and DFS 87.3% vs 58.2% and 64%, p=0.10, respectively).
Conclusion: MC is associated with more advanced tumor size and T stages, and therefore entails reduced rate of minimally invasive procedures. In our series, the absence of distant metastasis in the patients of MAC also had a positive effect on survival.
full-text links
full-text provider logo
Proceed to details Cite
Share
13
J BUON
Sep-Oct 2020;25(5):2228-2236.
Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer
Xifu Song 1, Jingjing Lu, Liyan Wang, Feifei Kong, Hangyu Yuan, Cheng Chen, Haixia Shan
Affiliations expand
PMID: 33277840
Free article
Abstract
Purpose: To explore the efficacy and safety of everolimus combined with endocrine therapy in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER-2)-negative advanced breast cancer.
Methods: The clinical information of 108 patients with HR-positive/HER-2-negative advanced breast cancer, who were admitted to and treated in our hospital from June 2014 to June 2016, was retrospectively analyzed. Of them, 54 patients were treated with everolimus combined with endocrine drugs (Everolimus group), while the other 54 patients underwent endocrine monotherapy (Control group). The clinical response rate and incidence of adverse reactions were compared between the two groups of patients, and the patients were followed up to record survival. Besides, the possible influencing factors for progression-free survival (PFS) were analyzed.
Results: The objective response rate (ORR) was 22.2% and 14.8%, respectively, in everolimus group and the Control group, while the clinical benefit rate (CBR) was 66.7% and 37.0%, respectively, in the two groups. There were statistically significant differences in the CBRs of the first-line and second-line therapies. The majority of adverse reactions were in grade I and II, with lower incidence rates of grade III and IV adverse reactions. The median PFS of the two groups of patients was 7.3±5.6 months and 6.7±5.1 months, respectively. The log-rank test revealed that there was a statistically significant difference in the PFS between the two groups of patients. According to the multivariate regression analysis results, progesterone receptor (PR)+, absence of visceral metastases, and sensitivity to endocrine therapy were the protective prognostic factors for PFS.
Conclusion: Everolimus combined with endocrine therapy has significant clinical efficacy in patients with HR-positive/HER-2-negative advanced breast cancer, and can effectively improve the survival of patients with tolerable adverse reactions. PR+, absence of visceral metastases and sensitivity to endocrine therapy are the protective prognostic factors for PFS.
full-text links
full-text provider logo
Proceed to details Cite
Share
14
J BUON
Sep-Oct 2020;25(5):2332-2340.
The expression and prognostic value of miR-195-5p in patients with advanced gastric cancer after chemotherapy
Wen Song 1, Zheng Cui, Hua Liu, Li Xue, Hui Ju
Affiliations expand
PMID: 33277853
Free article
Abstract
Purpose: To explore miR-195-5p expression and prognostic value in advanced gastric cancer (AGC) patients after chemotherapy.
Methods: 114 patients in total with AGC admitted to our hospital undergoing chemotherapy created the gastric cancer group, and 100 simultaneous healthy subjects undergoing physical examination created the normal group. MiR-195-5p level in both groups was detected.
Results: miR-195-5p level was evidently lower in the gastric cancer group, and miR-195-5p could be used in diagnosing gastric cancer patients. miR-195-5p was significantly associated with clinical stage and grade of differentiation. It was found that carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) were significantly negatively associated with miR-195-5p level before treatment in patients with AGC. Subjects were divided into effective group and ineffective group based on the therapeutic effect, mir-195-5p level in the ineffective group was notably lower than that in the effective group, and the serum miR-195-5p level was available for efficacy prediction. Patients were separated to high expression group and low expression group based on the median of the mir-195-5p expression. High expression group had remarkably better survival in comparison with the low expression group, and miR-195-5P expression of dead patients was lower than that of the surviving patients.
Conclusion: Serum miR-195-5p is decreased in AGC patients, and can be effectively utilized as a biomarker for the diagnosis and prognosis of patients with gastric cancer.
full-text links
full-text provider logo
Proceed to details Cite
Share
15
J BUON
Sep-Oct 2020;25(5):2237-2243.
Efficacy of oncoplastic breast-conserving surgery combined with intraoperative radiotherapy on early breast cancer
Quan Liu 1, Jun Fang
Affiliations expand
PMID: 33277841
Free article
Abstract
Purpose: To explore the efficacy and safety of oncoplastic breast-conserving surgery (OBCS) combined with intraoperative radiotherapy (IORT) in the treatment of early breast cancer (EBC).
Methods: The clinical data of 114 EBC patients treated in our hospital from January 2014 to May 2016 were retrospectively analyzed. The patients were divided into OBCS + IORT group (OBCS group, n=32) and standard BCS (SBCS) + IORT group (SBCS group, n=82) according to different treatment methods. The operation-related indexes, the weight of breast tissues resected, the surgical margin, the postoperative cosmetic effect on affected breasts and quality of life, the incidence of postoperative complications, postoperative tumor recurrence and patient's survival were compared between the two groups.
Results: The operation time of patients in OBCS group was significantly longer than in SBCS group, the amount of intraoperative blood loss and postoperative drainage was significantly smaller than in SBCS group, and the postoperative hospital stay was obviously shorter than in SBCS group. The incidence rates of postoperative hematoma and poor incision healing in OBCS group were obviously lower than in SBCS group. The weight of breast tissues resected, and minimum and maximum surgical margin were all evidently larger in OBCS group than in SBCS group. After operation, the excellent/good rate of breast appearance in OBCS group was significantly higher. After operation, the satisfaction with breast appearance, the score of each dimension in the short-form 36-item health survey questionnaire (SF-36) and average score in OBCS group were remarkably superior to those in SBCS group.
Conclusions: OBCS combined with IORT is safe and effective in the treatment of EBC, which can not only effectively ensure the surgical margin in BCS and reduce the incidence of surgical complications, but also obtain a better cosmetic effect and satisfaction with breast appearance, and improve the postoperative quality of life of patients.
full-text links
full-text provider logo
Proceed to details Cite
Share
16
J BUON
Sep-Oct 2020;25(5):2255-2264.
Identification of invasive key genes in breast cancer by bioinformatics analysis
Yi Quan 1, Song Wang
Affiliations expand
PMID: 33277843
Free article
Abstract
Purpose: Of all breast cancers, triple-negative and HER-2 positive are the most aggressive breast cancer subtypes with a high risk of recurrence and worse prognosis. The study's purpose was to further assess the molecular mechanisms underlying aggression of breast cancer.
Methods: The microarray gene expression datasets of GSE29431 and GSE53752 were obtained from the GEO (Gene Expression Omnibus) database, which include HER-2 positive breast cancer, triple-negative breast cancer (TNBC) and normal breast tissue samples. Differentially expressed genes (DEGs) were determined using the LIMMA package of R software and subsequently functional enrichment analysis were performed by the ClusterProfiler package in the R platform. The STRING database was used to construct a protein-protein interaction (PPI) network. The most significant module and key genes were identified by Cytoscape software. Utilizing the Kaplan-Meier plotter and UALCAN database, we defined the key genes associated with prognotic values and molecular subtypes as invasive genes.
Results: In total, 428 common DEGs were identified, including 143 upregulated and 285 downregulated. GO and KEGG pathway enrichment analysis indicated that the upregulated genes were associated with mitotic nuclear division and cell cycle, whereas the downregulated genes were significantly associated with response to peptide and PPAR signaling pathway, respectively. A PPI network with 57 nodes and 335 edges was established, from which one most significant module was identified. Moreover, 12 key genes selected from the module with high degree centrality more than 21 were highly associated with high clinical aggressiveness and worse overall survival rate.
Conclusions: Our studies could enhance the understanding of the molecular mechanism of breast cancer aggressiveness, and the identification of invasive key genes promoted the individualized and comprehensive treatment.
full-text links
full-text provider logo
Proceed to details Cite
Share
17
J BUON
Sep-Oct 2020;25(5):2482-2489.
Gene expression profiles and protein-protein interaction networks in neuroblastoma with MEIS2 depletion
Xin-Qian Hu 1, Ze An Weng, Ying Feng Xia, Yun Hong Zha
Affiliations expand
PMID: 33277872
Free article
Abstract
Purpose: The purpose of the present study was to identify differential gene expressions (DEGs) and key pathways in neuroblastoma with MEIS2 depletion through bioinformatics.
Methods: The microarray gene expression dataset GSE56003 was downloaded from the Gene Expression Omnibus (GEO) database. DEGs were identified using Gene Level RMA sketch and Transcriptome Analysis Console. Gene ontology (GO) function and KEGG pathway enrichment analysis of DEGs were performed using the DAVID online tool. Protein-protein interaction (PPI) networks were constructed by mapping the DEGs onto Cytoscape software. MCODE algorithm was used to select the module and Centiscape was used to screen the hub genes. The Kaplan-Meier survival curves was utilized to show the correlation of specific gene expressions and the survival situation of NB patients. Results：A total of 1352 DEGs were identified in neuroblastoma with MEIS2 depletion, which were mainly enriched during the cell cycle, DNA replication, and DNA repair. CDK2, RAD51, BRCA1, and MCM3 were selected as hub genes that have the potential as novel therapeutic targets for neuroblastoma.
Conclusion: This study revealed the hub genes and pathway involved in neuroblastoma with MEIS2 knockdown, which offered new insights into the molecular networks underlying MEIS2 depletion in neuroblastoma. Additionally, this study provided a valuable resource of potential biomarkers and therapeutic targets.
full-text links
full-text provider logo
Proceed to details Cite
Share
18
J BUON
Sep-Oct 2020;25(5):2490-2495.
Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib
Aydin Aytekin 1, Mehmet Naci Aldemir, Abdullah Sakin, Ufuk Telci, Ramazan Esen
Affiliations expand
PMID: 33277873
Free article
Abstract
Purpose: To determine whether there is a relationship between maximum standardized uptake (SUVmax) value of basal 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) that was performed before sunitinib treatment and treatment-related survival in patients with metastatic renal cell carcinoma (mRCC).
Methods: The data of 36 patients (female/male: 1/1, median age 57.36 years, range 31-74) were retrospectively analyzed in whom sunitinib treatment was started due to mRCC between 2008 and 2019 and who underwent basal 18F-FDG PET/CT examination before this treatment. The median SUVmax value was 6.8. Progression-free survival (PFS) and overall survival (OS) rates of patients, who had SUVmax value >6.8 (group I) (50%, n=18) and ≤ than 6.8 (group II) (50%, n=18), were compared.
Results: Both PFS and OS were significantly lower in the group with high SUVmax (SUVmax> 6.8, group I) before the sunitinib treatment than the group with low SUVmax (SUVmax ≤6.8, group II). When patients with SUVmax value> 6.8 (group I) (50%, n=18) and ≤6.8 (group II) (50%, n=18) were compared the median PFS of group I patients was 6.83 months (95%CI: 6.14-7.52), while the median PFS of group II patients was 11.24 months (95%CI: 8.4-14.06) (p=0.035). The median OS in group I and II was 12.91 months (95%CI: 10.17-15.65) and 54.54 months (95%CI: 8.51-100), respectively (p=0.042).
Conclusion: In this study it was found that PFS and OS were low in patients with high SUVmax value in 18F-FDG PET/CT performed before sunitinib treatment. As a result, 18F-FDG PET/CT SUVmax values measured before sunitinib treatment can be used to predict survival in mRCC patients.
full-text links
full-text provider logo
Proceed to details Cite
Share
19
J BUON
Sep-Oct 2020;25(5):2515-2522.
Expression and clinical value of miR-27a in serum of patients with skin squamous cell carcinoma
Hui Wang 1, Songfen Wang, Fang Chen, Chong Zhang, Xuguang Zhang, Yi Sun
Affiliations expand
PMID: 33277877
Free article
Abstract
Purpose: To investigate the expression and clinical value of miR-27a in the serum of patients with skin squamous cell carcinoma.
Methods: 70 patients with skin cancer diagnosed and treated in our hospital from July 2015 to July 2018 were selected as the experimental group, and 62 healthy patients with normal physical examination during the same period as the control group. The expression of miR-27a in serum of patients in both groups was detected by fluorogenic quantitative polymerase chain reaction (qRT-PCR). The expression levels of topoisomerase II (topo-II) and human epidermal growth factor receptor 2 (c-erbB-2) were detected by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve was used to analyze the predictive value of miR-27a for poor prognosis and the diagnostic value of miR-27a for skin squamous cell carcinoma.
Results: The expression levels of miR-27a, topo-II and c-erbB-2 of patients in the experimental group were significantly higher than those of the control group (p<0.001). The 3-year survival rate in the low miR-27a expression group was higher than that of the high expression group. The sensitivity, specificity and AUC of serum miR-27a in predicting the prognosis of skin cancer were 60.71%, 92.86%, 0.765, respectively.
Conclusions: The expression of miR-27a in tissue and serum was higher in patients with skin squamous cell carcinoma compared with healthy controls and was closely related to some pathological data of skin cancer. This miR can be used as a detection marker for screening and diagnosing skin squamous cell carcinoma and has a certain predictive value for prognosis.
full-text links
full-text provider logo
Proceed to details Cite
Share
20
J BUON
Sep-Oct 2020;25(5):2382-2388.
Research on the efficacy of laryngendoscopic low-temperature plasma ablation on early glottic cancer
Jianjun Jing 1, Liang Li, Liang Zheng, Yongxiang Wu, Songzi Jiang, Longfang Zhang, Hui Wang, Gang Liu
Affiliations expand
PMID: 33277859
Free article
Abstract
Purpose: To evaluate the efficacy and safety of self-retaining laryngendoscope-assisted low-temperature plasma ablation (LTPA) in the treatment of patients with early glottic cancer.
Methods: The clinical data of 84 patients with early glottic cancer treated in our department from May 2013 to May 2016 were collected. All patients were divided into the Plasma group (n=42, treated with the laryngendoscopic LTPA) and the Laryngofissure group (n=42, treated with traditional laryngofissure). The operation conditions, pain and cough visual analogue scale (VAS) scores, postoperative complications, mucosal recovery and voice recovery indexes were compared between the two groups, the postoperative recurrence rate was recorded, and the patients were followed up for tumor recurrence and survival.
Results: In the Plasma group, the operation time was significantly shorter than that in the Laryngofissure group, the amount of intraoperative bleeding was significantly less than that in the Laryngofissure group (p<0.001), and the postoperative hospitalization time was also significantly shorter than that in the Laryngofissure group. The postoperative pain and cough VAS scores in the Plasma group were obviously lower than those in the Laryngofissure group. The proportion of smooth vocal mucosa after operation in the Plasma group was evidently higher than that in the Laryngofissure group. In Plasma group, the voice parameters Jitter, Shimmer and harmonic to noise ratio (HNR) were all remarkably superior to those in the Laryngofissure group. The overall survival (OS) and progression-free survival (PFS) had no statistically significant differences between the two groups according to the log-rank test.
Conclusions: Self-retaining laryngendoscope-assisted LTPA has definite efficacy in the treatment of early glottic cancer, after which the recurrence rate and survival rate are similar to those after open laryngofissure, but LTPA is characterized by short operation time, less postoperative bleeding, quick recovery of patients and better voice recovery.
full-text links
full-text provider logo
Proceed to details Cite
Share |
No comments:
Post a Comment